ESTRO 2024 - Abstract Book

S2255

Clinical - Upper GI

ESTRO 2024

Mean Heart dose

All but 49 patients finished prescribed radiotherapy treatment and for neo-adjuvant treated patients, 92.4% proceeded to surgery. The median follow-up was 24 months with 30% still being alive at time of analysis. For neo adjuvant and definitive treatment, the median overall survival was 27 and 21 months, respectively (Figure 1).

46% had recurrent disease, of which 10% were oligometastatic recurrences. Median time to recurrence was 20 months. The frequency of patients with combined loco-regional and metastatic recurrence was similar between neo-adjuvant and definitive treated patients as well as between adenocarcinoma and squamous cell carcinoma patients. The risk of either recurrence or death without evidence of disease was highest for definitively treated squamous cell carcinoma patients (Figure 2).